Design Therapeutics
Cash Flow

Last updated:

Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Design Therapeutics generated cash of -$58,560,000, which is less than the previous year. Cash used in financing activities reached the amount of $724,000 last year. Net change in cash is therefore -$5,300,000.

Cash Flow

Design Therapeutics, Inc. (NASDAQ:DSGN): Cash Flow
2019 -139K 0 196K
2020 -8.66M -33.56M 44.53M
2021 -29.37M -53.64M 379.21K
2022 -51.31M -220.98M 235
2023 -58.56M 52.53M 724K

DSGN Cash Flow Statement (2019 – 2023)

2023 2022 2021 2020 2019
Cash at beginning of period
26.5M298.56M2.37M77K20K
Operating activities
Net income
-66.86M-63.30M-35.53M-8.28M-2.04M
Adjustments to reconcile net income to cash generated by operating activities:
Depreciation and amortization
537K406K129K5K0
Stock-based compensation expense
13.08M10.92M4.68M450K0
Deferred income tax benefit 13.08M10.92M4.68M450K0
Changes in operating assets and liabilities:
Accounts receivable, net
00000
Inventories
00000
Accounts payable
-1.24M5.38M2.41M-413K0
Cash generated by operating activities
-58.56M-51.31M-29.37M-8.66M-139K
Investing activities
Purchases Of Investments
-224.70M-312.99M-86.26M-55.58M0
Investments In Property Plant And Equipment
-256K-918K-1.53M-76K0
Acquisitions Net
039K52.10K33.48K0
Cash generated by investing activities
52.53M-220.98M-53.64M-33.56M0
Financing activities
Common Stock Issued
724K662K379.21M1K0
Payments for dividends
00000
Repurchases of common stock
305K339K000
Repayments of term debt
000-400K196K
Cash used in financing activities
724K235379.21K44.53M196K
Net Change In Cash
-5.3M-272.06M296.19M2.30M57K
Cash at end of period
21.2M26.5M298.56M2.37M77K
Data sourceData sourceData source